RGRomy Gadisseur

Romy Gadisseur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Romy Gadisseur has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Test results comparison: is the S-Monovette® Lithium-Heparin Gel+ a suitable replacement for the S-Monovette® Lithium-Heparin Gel on Alinity Abbott®?

    by Sqalli Ghali, Cavalier Etienne, Onkelinx Bérénice, Gadisseur Romy

    Article Test results comparison: is the S-Monovette® Lithium-Heparin Gel+ a suitable replacement for the S-Monovette® Lithium-Heparin Gel on Alinity Abbott®? was published on February 28, 2023 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).

  • Épidémiologie de la lithiase urinaire en Belgique sur base d’une classification morpho-constitutionnelle

    by Vincent Castiglione, François Jouret, Olivier Bruyère, Bernard Dubois, Alexandre Thomas, David Waltregny, Anne-Catherine Bekaert, Étienne Cavalier, Romy Gadisseur

    Urolithiasis is a common condition, with a prevalence of ∼10% and a male/female ratio above 1 according to large national series. Various types of urinary stones have been described upon their mineral content and/or their morphology. Hence, a combined morpho-constitutional (M-C) classification has been proposed. In order to detail the prevalence of urolithiasis in general and of each M-C type in particular upon age and gender in Belgium, we retrospectively studied the database of a reference center for urolithiasis analysis. Between 2010 and 2013, 2195 stones were characterized. We excluded 45 non-biological stones and 281 stones, which originated from outside the study zone. Among 1869 stones, 1293 (69.2%) affected men. Prevalence peak of urolithiasis was observed between 50-60 years of age in both genders. The M-C analysis was available for 1854 stones (99.2%): multiple morphological types were concomitantly identified in 49.3%. In the whole population, the main mineral constituent was whewellite (54.4%), mainly organized as type Ia (94%). Weddellite was found in 19.8%, with an equal distribution between types IIa and IIb. Uric acid was the 3rd most frequent constituent in man, with a similar distribution between IIIa and IIIb. Phosphate was uncommon in man (8.2%), but frequent in woman (26.6%) with a type IVa1 organization. Prevalence of M-C types changes with aging, i.e. decrease of weddellite and increase of whewellite and uric acid in both genders. This retrospective analysis of a single-center database of urinary stones helps characterize the M-C epidemiology of urolithiasis in Belgium.


  • Épidémiologie de la lithiase urinaire en Province de Liège

    by R. Gadisseur, V. Castiglione, F. Jouret, O. Bruyère, A.C. Bekaert, A. Thomas, B. Dubois, D. Waltrégny, E. Cavalier

    Introduction: L’analyse morpho-constitutionnelle des lithiases urinaires aboutit à une classification qui fournit des données précieuses sur les pathologies à l’origine de la lithogenèse. Le but de notre étude est de présenter les premières données épidémiologiques belges sur les lithiases sur base de cette méthode d’analyse. Patients et méthodes Nous avons étudié rétrospectivement 1869 analyses morpho-constitutionnelles de lithiases issues de la Province de Liège et reçues sur 3 années. Pour chacune, nous avons étudié différents paramètres comme l’âge et le sexe du patient, la composition quantitative relative de chaque constituant, le nombre de constituants et le type morphologique. Résultats: Chez l’adulte, le ratio hommes/femmes est de 2,25. Il est < 1 entre 10 et 20 ans. Les épisodes lithiasiques sont plus fréquents entre 50 et 60 ans. Les calculs sont purs dans 31 % des cas. Parmi les lithiases de Whewellite pure, 94 % sont de type Ia et sont plus fréquentes chez les hommes. Chez l’homme de 20–30 ans, la Weddellite est le principal composant alors que la Whewellite est plus fréquente par la suite pour atteindre 60 % à 50-59 ans. Parmi les autres composants majoritaires, on dénombre 9,4 % d’acide urique et 2,5 % de Struvite. Le pourcentage de lithiases uriques de type IIIa/IIIb croît avec l’âge et atteint 20 % dès 60 ans. La fréquence des lithiases de phosphates calciques est stable durant la vie mais double au-delà de 80 ans. Le type morphologique IVa est celui pour lequel il existe le plus de disparités entre les deux sexes. Chez les femmes, 21,5 % des calculs sont phosphatiques. Ainsi, les types IVa1 et IVa2 sont plus fréquents chez les femmes. Les phosphates calciques sont d’ailleurs les seconds composés les plus rencontrés chez la femme au-delà de 30 ans. Dix pourcents des calculs sont de type IVa1 associé à la présence de Weddellite. Discussion et conclusion Cette étude épidémiologique fournit un recensement de la maladie lithiasique en Province de Liège et est la première étude chez l’adulte se basant sur l’analyse morpho-constitutionnelle.

    • 1 January 2012
      • Vol. 58, 515-25

    Multicentre evaluation of a second generation point-of-care assay with an extended range for the determination of N-terminal pro-brain natriuretic peptide.

    by Bo Jørgensen, Thomas Bertsch, Hans-Joachim Bröker, Markus Schäfer, Jean-Paul Chapelle, Romy Gadisseur, Martin R Cowie, Bert Dikkeschei, Eberhard Gurr, Wiebke Hayen, et al.

    In the second generation of the point-of-care (POC) assay Roche CARDIAC proBNP, the upper limit of the measuring range was extended from 3000 to 9000 ng/L. A thirteen-site multicentre evaluation was carried out to assess the analytical performance of the POC NT-proBNP assay and to compare it with a laboratory N-terminal pro-brain natriuretic peptide (NT-proBNP) assay. In method comparisons of six lots of POC NT-proBNP with the lab reference method (Elecsys proBNP) mean bias ranged from -10 to +17%. In lot-to-lot comparisons all six investigated lots of POC NT-proBNP showed excellent agreement, with mean bias between -7% and +2%. The majority of all coefficients of variation obtained from ten-fold measurements using 56 native blood samples were below 8%. No interference was observed with hemolytic blood (hemoglobin concentrations up to 0.12 mmol/L), lipemic blood (triglyceride concentrations up to 14.0 mmol/L) nor icteric blood (bilirubin concentrations up to 63 micromol/L). Hematocrit values between 24% and 51% had no influence on the assay result. High NT-proBNP concentrations above the measuring range of POC NT-proBNP did not lead to false low results due to potential high-dose hook effect. Results with POC NT-proBNP were not influenced by different ambient temperatures (18 degrees C to 32 degrees C), the sample material used, nor by over- or underdosing by 15 microL compared to the regular sample volume of 150 microL. The POC NT-proBNP assay showed an excellent analytical performance including a good agreement with the laboratory method. The assay is therefore suitable for its intended use in point-of-care settings.


  • A new tool in the field of in-vitro diagnosis of allergy: preliminary results in the comparison of ImmunoCAP© 250 with the ImmunoCAP© ISAC

    by Romy Gadisseur, Jean-Paul Chapelle, Etienne Cavalier

    Background: The ImmunoCAP© ISAC allows for the determination of specific immunoglobulin E (IgE) against 103 recombinant or purified allergen components in a single analytical step. The aim of our study was to perform a comparison of the specific IgE results measured with the microarray method to those obtained using the traditional method of ImmunoCAP©. Methods: We selected 86 clinically relevant patients on the basis of their specific IgE for recombinant allergens (ImmunoCAP© 250, Phadia). Also, we selected two patients with a high total IgE to evaluate the non-specific binding of IgE. All samples were screened with the ImmunoCAP© ISAC. Then, we compared the 555 specific IgE antibodies results provided by ImmunoCAP© ISAC with the specific IgE levels obtained with ImmunoCAP© 250. Results: We observed that 82 of the 384 results found to be positive with ImmunoCAP© were negative with ISAC© (concordance 78.65%). Of 171 negative results obtained with ImmunoCAP©, 11 were positive with ISAC© (concordance 93.57%). No non-specific binding was observed. Conclusions: Our results show that the ImmunoCAP© ISAC has good analytical performance when compared with the ImmunoCAP© 250 method. We did not observe any non-specific binding. However, better sensitivity for some clinically relevant allergen components, such as rPru p 3 is needed.